Case report

Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review

C. Pérez-Guzmán a, R. Barrera-Rodríguez b,*, J. Portilla-Segura a

a Hospital General Tercer Milenio. Instituto de Salud del Estado de Aguascalientes, Av. Siglo XXI s/n Col. Satélite Morelos, Aguascalientes 20140, México
b Depto. de Bioquímica y Medicina Ambiental, Instituto Nacional de Enfermedades Respiratorias-SSA, Clzla. Tlalpan, 4502, Col Sec. XVI. México, D.F., 14080, México

1. Background

Malignant pleural mesothelioma (MPM) is a rare, aggressive and hard-to-treat malignant neoplasm that commonly develops in pleura and peritoneum [1]. Approximately 80% of MPM patients have a history of exposure to asbestos [2]. However, it can take decades to develop and, as a result, is usually thought of as a disease of middle age and elder people [2]. Patients with MPM frequently develop thoracic pain, dyspnea, weight loss and pleural effusion [3]. Unusual presentations have also been reported, though rarely [4,5]. Although rare, pleural mesothelioma does occur in the young; their characteristics are different from those of older patients [6]. We report a case of a teenager who had a large malignant pleural effusion.

2. Case presentation

A 17-year old male patient was admitted to our hospital on June 2015. He had smoked tobacco and marijuana cigarettes for three months the previous year, as well as moderate alcohol consumption. The patient was diagnosed with allergic rhinitis and bronchial hyperreactivity at the age of 12 years old without regular treatment. At hospital admission, he had 7 days with fixed moderate dyspnea, fever, right-sided pleuritic chest pain, headache, cough and no weight loss. Physical examination showed a homogenous opacity on lower right hemithorax. Biochemical analysis of pleural fluid showed hemorrhagic/turbid effusion compatible with exudate. It was initially treated as an empyema. Physical examination showed a right pleural effusion and chest roentgenograms revealed a homogenous opacity on lower right hemithorax. Biochemical analysis of pleural fluid showed hemorrhagic/turbid effusion compatible with exudate. It was initially treated as an empyema. The pleural fluid culture was negative. Adenosine deaminase level was 34.3 U/L (admission) and 19.02 U/L (two weeks after). Pleural fluid smear and culture for Mtb were negative. During the open pleural biopsy, thickened pleura and multiple pale yellow nodules in the lung were observed. The histopathological report was compatible with malignant pleural mesothelioma. With this diagnosis, a chemotherapy regimen with cisplatin was initiated. After two cycles, the patient had no clinical and radiological improvement. The patient is currently under regular follow up.

Conclusion: MPM is rare in young adults and its clinical presentation makes it different from mesothelioma in elderly patients, so it will be necessary to identify the new risk factors that can identify these patients.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The next day, the patient had relief of symptoms, reporting mild pain only at the chest-tube insertion site. A second chest X-ray showed a fully re-expanded left lung (Fig. 2). For the next 7 day at least 750 ml daily of clear pleural fluid was drained. Biochemical analysis of pleural fluid demonstrated an exudate with very low glucose level 0.20 mg/dl. Pleural fluid cultures were negative. Because of the increase of pleural fluid drainage up to 800 ml daily, we decided to perform a closed pleural biopsy, which reported negative results for tuberculosis and malignancy.

At admission, the adenosine deaminase (ADA) level was 34.3 U/L in two weeks it decreased to 19.02 U/L. Acid-fast bacilli (AFB) for pleural fluid was negative, and culture for Mtb remained negative.

In spite of antibiotics, pleural fluid drainage did not decrease after 3 weeks, thus we decided to begin the anti-TB treatment. However, after another week, no decrease in pleural fluid drainage was observed. Therefore, we decided to perform an open pleural biopsy. During surgery, pleural thickening and multiple pale yellow nodules in the lung were seen. After a diagnosis of malignancy, pleurodesis was done twice with povidone-iodine but no decrease in pleural fluid drainage was obtained.

Unfortunately, the patient did not receive other treatment such as pemetrexed, gemcitabine because they were not available at that moment, and extrapleurectomy is not a common surgical procedure in our media.

Immunohistochemistry revealed tumor cells to be immunoreactive for calretinin (clone Z11-E3, Dako) cytokeratin 7 (BC-1, BIOCARE MEDICAL) and negative for WT1 (BC.6F–H2, BIOCARE MEDICAL) NAPSIN A (TMU-Ad 02, BIOCARE MEDICAL). Based on these findings; the cause of pleural effusion was diagnosed as MPM. With this diagnosis, a chemotherapy regimen with cisplatin was initiated [7]. After two cycles, there was no clinical and radiological improvement. The patient is currently under regular follow up.

3. Discussion

The worldwide MPM incidence has been rising since the mid 20th century [8,9]. MPM is often considered a disease of the elderly with a median age of 74 years [10]. However, there is a subgroup of patients who are young [6]. Here, we showed the case of a teenager with massive pleural effusion, diagnosed with MPM and a review of the literature. As far as we know, this is one of the few younger patients with MPM reported until now.

Fig. 1. Initial Chest X-ray demonstrated a large right pleural effusion, that occupies 2/3 parties of the right hemithorax accompanied with fever and right chest pain.

Fig. 2. Chest X-ray demonstrated total lung reexpansion after thoracic tube insertion. Mild pleural thickness is observed.

To date, numerous epidemiological reports describe the elderly population with MPM but outside of case studies [11,12], and small cohorts [13,14] a detailed examination of young patients with MPM has been less studied. An important finding of these reports is that almost 15% of cases with MPM were younger than the age 40 [14–17]. In addition, other case-series have also found a lower frequency for patients with MPM under 40 years old: i.e. Kane et al. found ten of 172 cases (5.8%) [18], whereas Jones and Thomas in a review of 5778 death certificates reported 298 cases (5.2%) between the ages of 15 and 44 at the time of death [19]. The Surveillance, Epidemiology, and End Results (SEER) database for mesothelioma cases from 1990 to 2010 showed that about 2% (207) of the 12,345 mesothelioma cases studied occurred in people under 40 years old [20].

Malignant mesothelioma (MM) in young people acts very differently than it does in the older population. Thus, while almost 80% of the older MPM patients are men, the disease is about equally split between men and women in the younger age group [21]. Another difference between younger and older mesothelioma patients is the frequency of pleural and peritoneal mesothelioma. The two types of mesothelioma are about evenly distributed in the younger patients while 90% of older patients have the pleural variety [21]. The younger group is also more likely to undergo cancer-directly to surgery and to live longer afterward, even if they have a type of mesothelioma that is usually considered less survivable [22,23].

Most of the elderly patients diagnosed with mesothelioma die of the disease within a year of diagnosis. Improved overall survival of the young mesothelioma patients with both pleural and peritoneal mesothelioma indicates that mesothelioma in the young may possibly have a different natural history and indeed be biologically different from mesothelioma in elderly patients. Genomic and expression studies of tumor samples from young and old patients with mesothelioma will clarify the biological differences between the two cohorts. To our knowledge, no such studies have been conducted to date.

The relationship between MM and asbestos exposure it is well-known. The latency period of MM is highly variable and can be as short as 13 years or as long as 70, between exposure and diagnosis [24]. Because of this long time span, most of those who are diagnosed with MPM and other asbestos-related disease are in their 60s or 70s.

MPM in young patients with occupational and non-occupational
asbestos exposure has been documented in a few case reports [12,18,25], and small population cohorts [26]. For instance, considering the long latency period, MPM in the young boys is less likely due to occupational exposure to asbestos fibers [24]. Interestingly, in a cohort of adults that had lived in a blue asbestos mining town during their childhood, Reid et al. found lower mortality rates among individuals exposed to asbestos when they were 15 years old and younger compared to adults with similar exposures who were first exposed when they were 15 years old or older [26]. Occasionally, MPM is seen in young patients with no exposure history. Brenner et al. described in 1981 seven cases <17 years old with non-asbestos related mesothelioma, six of them had pleural involvement, from these, one survived after surgery and chemotherapy after 5 years of follow-up [27]. Thus, in young MPM patients it is likely that increased genetic predisposition and/or environmental exposure to carcinogenic mineral fibers from an early age are possible etiological factors in these patients [28]. A genetic component in the etiology of the disease might in part explain the relative rarity of MPM in young people. Recent studies have identified germline mutations in the gene encoding BRCA1 associated protein–1 (BAP1) which can predispose to MPM [29,30]. Mesothelioma occurring in germline BAP1 mutation carriers have been reported to be less aggressive clinically and associated with prolonged survival compared with sporadic MPM [31]. In addition, germline BAP1 mutations confer increased susceptibility for the development of several other tumors including uveal melanoma, cutaneous melanoma, renal cell cancers and possibly other cancers [32]. Because our patient does not have a report of familiar clustering of cancer, germline BAP1 mutations alone cannot explain the development of MPM. Other candidate gene-based association studies have also identified other genes that may play an additional role in the development of this neoplasm [33]. Further research is needed to better understand how genetic susceptibility or other risk factors interact to cause mesothelioma in certain younger people.

Younger patients with rare cancers such as those with mesothelioma require multidisciplinary care and are more likely to be referred to large international cooperative groups to facilitate the study of these infrequent tumors and develop registries, bio-specimen banks, and clinical trials for these diseases [34]. Active participation in these organizations could potentially offer invaluable information with regards to the incidence and numbers of new patients with childhood mesothelioma and could, therefore, facilitate the planning of epidemiologic, biologic, and therapeutic trials for this patient population.

4. Conclusion

This case is reported because malignant pleural mesotheliomas are a rare cause of pleural effusion in the clinical practice among younger adults. Additionally, the clinical presentation of MPM in young adults is different from MPM in elderly patients. We believe that this case together with all those reported in the literature suggests that mesotheliomas of young people are a different neoplasm entity from elderly patients and should be treated differently. Likewise, further clinical and epidemiological studies will be necessary to identify the new risk factors in these patients.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Funding

None.

Authors’ contributions

CPG was the primary person responsible for the writing of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

To Mrs. Naomi Ybarra for linguistic revision of the manuscript. Special thanks to Dr Jorge Morales Fuentes for critical reading of the manuscript.

References

[1] D. Rodriguez, M.C. Cheung, N. Housri, L.G. Koniaris, Malignant abdominal mesothelioma: defining the role of surgery, J. Surg. Oncol. 99 (2009) 51–55.
[2] D.H. Yates, B. Corrin, P.N. Stedolph, K. Browne, Malignant mesothelioma in southwest England: clinicopathological experience of 272 cases, Thorax 52 (1997) 507–512.
[3] British Thoracic Society Standards of Care Committee, BTS statement on malignant pleural mesothelioma in the UK, 2007, Thorax 62 (2007) ii1–ii9.
[4] J.G. Tannock, J. Schiller, J.A. Groome, P. Gervais, A. Halhuber, et al., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J. Clin.Oncol 21 (2003) 2435–2444.
[5] C. Bianchi, T. Bianchi, Malignant mesothelioma: global incidence and relationship with asbestos, Ind. Health 45 (2007) 379–387.
[6] B. Price, A. Ware, Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005, Crit. Rev. Toxicol. 39 (2009) 576–588.
[7] Malignant mesothelioma: Number of deaths by sex, race, median age at death, and anatomical site, U.S. residents age 15 and over, 1999–2007. In Mortality multiple cause-of-death data from National Center for Health Statistics, National Vital Statistics System. http://www.cdc.gov/ewords/Data/Malignant_mesothelioma_Number_of_deaths_by_sex_race_age_group_and_median_age_at_death_US_residents_age_15_and_over_20012010/434.
[8] A.D. McDonald, A. Harper, O.A. El Attar, J.C. McDonald, Epidemiology of primary malignant mesothelial tumors in Canada, Cancer 26 (1970) 914–919.
[9] J. Brenner, P.P. Sordillo, G.B. Magill, R.B. Golbey, Malignant mesothelioma of the pleura. Review of 123 cases, Cancer 49 (1982) 2431–2435.
[10] M.J. Kane, A.P. Chahinian, J.F. Holland, Malignant mesothelioma in young adults, Cancer 65 (1990) 1449–1455.
[11] E. Blichatchi, K. Kayser, M. Perelman, E.D. Richter, Mesothelioma and asbestos in a young woman following occupational asbestos exposure: Short latency and long survival: Case Report, Diagn Pathol. 5 (2010) 81.
[12] G.W. Grundy, R.W. Miller, Malignant mesothelioma in childhood. Report of 13 cases, Cancer 30 (1972) 1216–1218.
[13] A.A. Hochberg, Endothelioma (mesothelioma) of the pleura, Am. Rev. Tuberc. 63 (1951) 150–173.
[14] P.C. Elmes, M.J.C. Simpson, The clinical aspects of mesothelioma, Q. J. Med. 179 (1976) 427–449.
[15] A.D. McDonald, A. Harper, O.A. El Attar, J.C. McDonald, Epidemiology of primary malignant mesothelial tumors in Canada, Cancer 26 (1970) 914–919.
[16] J. Brenner, P.P. Sordillo, G.B. Magill, R.B. Golbey, Malignant mesothelioma of the pleura. Review of 123 cases, Cancer 49 (1982) 2431–2435.
[17] M.J. Kane, A.P. Chahinian, J.F. Holland, Malignant mesothelioma in young adults, Cancer 65 (1990) 1449–1455.
[18] B. Jones, P. Thomas, Incidence of mesothelioma in Britain (Letter), Lancet 1 (1986) 127.
[19] Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With County, Total U.S. (1990-2010) - Linked To County Attributes - Total U.S., 1969-2011 Countries.
[20] A. Thomas, Y. Chen, T. Yu, A. Gill, V. Prasad, Distinctive clinical characteristics of malignant mesothelioma in young patients, Oncotarget 6 (2015) 16769–16773.
[21] M.J. Kane, A.P. Chahinian, J.F. Holland, Malignant mesothelioma in young adults, Cancer 65 (1990) 1449–1455.
of malignant mesothelioma in young patients, Oncotarget 6 (2015) 16766–16773.

[22] A.L. Feldman, S.K. Libutti, J.F. Pingpank, D.L. Bartlett, T.H. Beresnev, S.M. Mavroukakis, S.M. Steinberg, D.J. Liewehr, D.E. Kleiner, H.R. Alexander, Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy, J. Clin. Oncol. 21 (2003) 4560–4567.

[23] J.E. Herndon, M.R. Green, A.P. Chahinian, J.M. Corson, Y. Suzuki, N.J. Vogelzang, Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B, Chest 113 (1998) 723–731.

[24] B.P. Lanphear, C.R. Buncher, Latent period for malignant mesothelioma of occupational origin, J. Occup. Med. 34 (1992) 718–721.

[25] C. Pérez-Guzmán, M.H. Vargas, L. Torre-Bouscoud, Mesotelioma pleural. Similitudes clínico-radiológicas entre estirpes, Rev. Med. Inst. Mex. Seguro Soc. 46 (2008) 561–566.

[26] A. Reid, P. Franklin, N. Olsen, J. Sleith, L. Samuel, P. Aboagye-Sarfo, N. de Klerk, A.W. Mask, All-cause mortality and cancer incidence among adults exposed to blue asbestos during childhood, Am. J. Ind. Med. 56 (2013) 133–145.

[27] J. Brenner, P.P. Sordillo, G.B. Magill, Malignant mesothelioma in children: report of seven cases and review of the literature, Med. Pediatr. Oncol. 9 (1981) 367–373.

[28] M. Carbon, S. Emri, A.U. Dogan, I. Steele, M. Tuncer, H.I. Pass, Y.I. Baris, A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes, Nat. Rev. Cancer 7 (2007) 147–154.

[29] J.R. Testa, M. Cheung, J. Pei, J.E. Below, Y. Tan, E. Sementino, N.J. Cox, A.U. Dogan, H.I. Pass, S. Trusa, M. Hesdorffer, M. Nasu, A. Powers, Z. Rivera, S. Comertpay, M. Tanji, G. Gaudino, H. Yang, M. Carbone, Germine BAP1 mutations predispose to malignant mesothelioma, Nat. Genet. 43 (2011) 1022–1025.

[30] J. Xu, Y. Kadariya, M. Cheung, J. Pei, J. Talarchek, E. Sementino, Y. Tan, C.W. Menges, K.Q. Cai, S. Litwin, H. Peng, J. Karar, F.J. Rauscher, J.R. Testa, Germine mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma, Cancer Res. 74 (2014) 4388–4397.

[31] F. Baumann, E. Flores, A. Napolitano, S. Kanodia, E. Taioli, H. Pass, H. Yang, M. Carbone, Mesothelioma patients with germine BAP1 mutations have 7-fold improved long-term survival, Carcinogenesis 36 (2015) 76–81.

[32] M. Carbon, H. Yang, H.I. Pass, T. Krausz, J.R. Testa, G. Gaudino, BAP1 and cancer, Nat. Rev. Cancer 13 (2013) 153–159.

[33] S. Tunesi, D. Ferrante, D. Mirabelli, S. Andorno, M. Betti, G. Florito, S. Guarera, E. Casalone, M. Neri, D. Ugolini, S. Bonassi, G. Matteo, L. Dianzani, E. Magnani, Gene-asbestos interaction in malignant pleural mesothelioma susceptibility, Carcinogenesis 36 (2015) 1129–1135.

[34] A.S. Pappo, W.L. Furman, K.A. Schultz, A. Ferrari, L. Helman, M.D. Kralio, Rare Tumors in Children: Progress Through Collaboration, J. Clin. Oncol. 33 (2015) 3047–3054.